Simplify Logo

Full-Time

Associate Scientist

CMC Analytical Development

Confirmed live in the last 24 hours

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Biotechnology
Healthcare

Compensation Overview

$57k - $68kAnnually

Entry, Junior

Fitchburg, WI, USA

Category
Lab & Research
Life Sciences
Required Skills
Mergers & Acquisitions (M&A)
Requirements
  • B.S. in Chemistry (or related area of study)
  • Entry level with 1-3 years of experience working in a chemistry laboratory setting
  • Familiar with analytical instrumentation, test methodology/validations, data acquisition systems, and cGMP policies and practices
  • Ability to correctly analyze data/results and interpret outcome of experiments and to propose appropriate follow-up
  • Strong attention to detail
  • Works well with others and in a team environment
  • Can be flexible with changing priorities
Responsibilities
  • Know and adhere to cGMP policies and procedures and relevant SOPs
  • Work closely with team members to provide accurate analytical results in support of new and on-going projects
  • Work with supervision to meet project timelines and deliverables
  • Perform testing of samples to support batch release and stability studies
  • Learn and perform portions of analytical techniques, such as HPLC, GC, FTIR, UV/Vis, LC/MS, KF, etc.
  • Assist with the design and initiation for development of analytical methods and improvement of existing ones to support all stages of drug development process
  • Train and participate in evaluation and interpretation of scientific data and provide the significance of such
  • Assist in the design and execution of routine experiments
  • Participate in analysis of data/results and interpret outcome of experiments and assist in determining appropriate follow-up
  • Compile data tables of results and certificate of analysis, develop stability reports
  • Calibrate, maintain, and troubleshoot simple analytical equipment
  • Other duties as assigned
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing specific genes. The company uses RNA interference (RNAi), a natural process that reduces gene expression, to create therapies that can potentially stop or reverse diseases like cystic fibrosis and hepatitis B. Their approach involves a variety of RNA chemistries and effective delivery methods to ensure that the target genes are significantly reduced in activity. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, which allows them to address medical needs that are not met by existing treatments. The goal of Arrowhead Pharmaceuticals is to provide new treatment options for patients suffering from genetic disorders, leveraging their expertise and partnerships to bring these therapies to market.

Company Stage

IPO

Total Funding

$899.9M

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Arrowhead's recent $450 million funding round provides substantial financial resources to advance its drug pipeline and expand research initiatives.
  • Positive Phase 2 data for plozasiran and the initiation of an Expanded Access Program highlight the company's commitment to addressing unmet medical needs.
  • The company's diversified pipeline, including treatments for cystic fibrosis, hepatitis B, and myotonic dystrophy, offers multiple avenues for success.

What critics are saying

  • The high costs and lengthy timelines associated with drug development could strain Arrowhead's financial resources despite recent funding.
  • Regulatory hurdles and the potential for clinical trial failures pose significant risks to the company's drug approval process.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead Pharmaceuticals leverages RNA interference (RNAi) technology to target and silence disease-causing genes, setting it apart from traditional pharmaceutical approaches.
  • The company's proprietary TRiM platform enables tissue-specific targeting, enhancing the efficacy and safety of its therapies.
  • Strategic partnerships with major pharmaceutical companies like Takeda bolster Arrowhead's credibility and expand its research capabilities.